M1674 Gender-Specific Differences in CD4+CD25+FOXP3+ Natural T Regulatory Cells Modulate Chronic Intestinal Inflammation in Experimental Crohn's Disease

2009 ◽  
Vol 136 (5) ◽  
pp. A-407-A-408
Author(s):  
Rekha R. Garg ◽  
Muhammadreza A. Sachedina ◽  
Brian K. Reuter ◽  
Theresa T. Pizarro
2010 ◽  
Vol 4 (1) ◽  
pp. 29
Author(s):  
P. Biancheri ◽  
A. Di Sabatino ◽  
S. Piconese ◽  
M. Rosado ◽  
R. Carsetti ◽  
...  

2009 ◽  
Vol 23 (S1) ◽  
Author(s):  
Rekha Rani Garg ◽  
Muhammad A Sachedina ◽  
Fabio Cominelli ◽  
Brian K Reuter ◽  
Emilie F Rissman ◽  
...  

2008 ◽  
Vol 19 ◽  
pp. S44
Author(s):  
Antonio Di Sabatino ◽  
Manuela Rosado ◽  
Paolo Biancheri ◽  
Paolo Cazzola ◽  
Laura Rovedatti ◽  
...  

2001 ◽  
Vol 96 (3) ◽  
pp. 822-828 ◽  
Author(s):  
Shigeo Kanazawa ◽  
Tsukasa Tsunoda ◽  
Eishi Onuma ◽  
Toshimitsu Majima ◽  
Mitsuyasu Kagiyama ◽  
...  

1995 ◽  
Vol 182 (5) ◽  
pp. 1281-1290 ◽  
Author(s):  
M F Neurath ◽  
I Fuss ◽  
B L Kelsall ◽  
E Stüber ◽  
W Strober

In this study, we describe a novel murine model of chronic intestinal inflammation induced by the hapten reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS). Rectal application of low doses of TNBS in BALB/c and SJL/J mice resulted in a chronic transmural colitis with severe diarrhea, weight loss, and rectal prolapse, an illness that mimics some characteristics of Crohn's disease in humans. The colon of TNBS-treated mice on day 7 was marked by infiltration of CD4+ T cells; furthermore, in situ polymerase chain reaction studies revealed high levels of interferon (IFN)-gamma mRNA in diseased colons. Isolated lamina propria (LP) CD4+ T cells from TNBS-treated mice stimulated with anti-CD3 and anti-CD28 antibodies exhibited a Th1 pattern of cytokine secretion: a 20-50-fold increase in IL-2 and IFN-gamma levels and a 5-fold decrease in IL-4 levels as compared with those of stimulated LP CD4+ T cells from control BALB/c mice. Administration of monoclonal anti-IL-12 antibodies to the TNBS-treated mice both early (at 5 d) and late (at 20 d) after induction of colitis led to a striking improvement in both the clinical and histopathological aspects of the disease and frequently abrogated the established colitis completely. Furthermore, LP CD4+ T cells isolated from anti-IL-12-treated mice failed to secrete IFN-gamma upon in vitro stimulation. In summary, the data demonstrate the pivotal role of IL-12 and IFN-gamma in a TNBS-induced murine model of chronic intestinal inflammation. Furthermore, they suggest the potential utility of anti-IL-12 antibodies in patients with Crohn's disease.


2013 ◽  
Vol 144 (5) ◽  
pp. S-422
Author(s):  
Veena Tiwari ◽  
Saurabh Kedia ◽  
Pratap Mouli Venigalla ◽  
Dipendra K. Mitra ◽  
Siddhartha Datta Gupta ◽  
...  

2008 ◽  
Vol 40 ◽  
pp. S43-S44
Author(s):  
A. Di Sabatino ◽  
M. Rosado ◽  
P. Biancheri ◽  
P. Cazzola ◽  
L. Rovedatti ◽  
...  

2021 ◽  
Vol 27 (Supplement_2) ◽  
pp. S33-S37 ◽  
Author(s):  
Jean-Paul Motta ◽  
Celine Deraison ◽  
Sylvie Le Grand ◽  
Bruno Le Grand ◽  
Nathalie Vergnolle

Abstract A new paradigm has been added for the treatment of inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. In addition to resolving symptoms and inflammatory cell activation, the objective of tissue repair and mucosal healing is also now considered a primary goal. In the search of mediators that would be responsible for delayed mucosal healing, protease-activated receptor-1 (PAR-1) has emerged as a most interesting target. Indeed, in Crohn’s disease, the endogenous PAR-1 agonist thrombin is drastically activated. Activation of PAR-1 is known to be associated with epithelial dysfunctions that hamper mucosal homeostasis. This review gathers the scientific evidences of a potential role for PAR-1 in mucosal damage and mucosal dysfunctions associated with chronic intestinal inflammation. The potential clinical benefits of PAR-1 antagonism to promote mucosal repair in CD patients are discussed. Targeted local delivery of a PAR-1 antagonist molecule such as CVT120165, a formulated version of the FDA-approved PAR-1 antagonist vorapaxar, at the mucosa of Crohn’s disease patients could be proposed as a new indication for IBD that could be rapidly tested in clinical trials.


Sign in / Sign up

Export Citation Format

Share Document